Phase 1 study of ARQ 761, a β-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis (Q57461599)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30318513%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

title

Phase 1 study of ARQ 761, a β-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30318513%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30318513%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

author name string

David E Gerber

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30318513%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

M Shaalan Beg

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30318513%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Farjana Fattah

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30318513%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Oluwatomilade Fatunde

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30318513%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Yull Arriaga

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30318513%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Jonathan E Dowell

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30318513%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Ajit Bisen

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30318513%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Richard D Leff

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30318513%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Claudia C Meek

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30318513%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

William C Putnam

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30318513%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Raja Reddy Kallem

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30318513%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Indhumathy Subramaniyan

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30318513%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Ying Dong

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30318513%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Joyce Bolluyt

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30318513%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Venetia Sarode

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30318513%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Xin Luo

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30318513%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Yang Xie

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30318513%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

David A Boothman

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30318513%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

Arthur E Frankel

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30318513%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

language of work or name

English

0 references

publication date

15 October 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30318513%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Cancer

28 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30318513%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

volume

119

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30318513%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30318513%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

page(s)

928-936

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30318513%20AND%20SRC:MED&resulttype=core&format=json

NAD(P)H:Quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity

28 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0278-4

7 January 2021

New tricks for old drugs: the anticarcinogenic potential of DNA repair inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0278-4

7 January 2021

DT-diaphorase and cytochrome B5 reductase in human lung and breast tumours

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0278-4

7 January 2021

NAD(P)H:quinone oxidoreductase1 (DT-diaphorase) expression in normal and tumor tissues

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0278-4

7 January 2021

Efficacy of beta-lapachone in pancreatic cancer treatment: exploiting the novel, therapeutic target NQO1.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0278-4

7 January 2021

Intratumoral delivery of beta-lapachone via polymer implants for prostate cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0278-4

7 January 2021

An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0278-4

7 January 2021

Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0278-4

7 January 2021

Potent inhibition of tumor survival in vivo by beta-lapachone plus taxol: combining drugs imposes different artificial checkpoints

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0278-4

7 January 2021

Susceptibility of cancer cells to beta-lapachone is enhanced by ionizing radiation.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0278-4

7 January 2021

Mitomycin: ten years after approval for marketing

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0278-4

7 January 2021

Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0278-4

7 January 2021

Enhancement of solubility and bioavailability of beta-lapachone using cyclodextrin inclusion complexes

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0278-4

7 January 2021

Beta-lapachone-containing PEG-PLA polymer micelles as novel nanotherapeutics against NQO1-overexpressing tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0278-4

7 January 2021

Selective killing of cancer cells by beta -lapachone: direct checkpoint activation as a strategy against cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0278-4

7 January 2021

Genotyping of NAD(P)H:quinone oxidoreductase (NQO1) in a panel of human tumor xenografts: relationship between genotype status, NQO1 activity and the response of xenografts to Mitomycin C chemotherapy in vivo(1).

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0278-4

7 January 2021

Pharmacokinetics and tolerability of MB12066, a beta-lapachone derivative targeting NAD(P)H: quinone oxidoreductase 1: two independent, double-blind, placebo-controlled, combined single and multiple ascending dose first-in-human clinical trials.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0278-4

7 January 2021

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0278-4

7 January 2021

Methemoglobinemia and hemolytic anemia caused by rasburicase administration in a newly diagnosed child with Burkitt lymphoma/leukemia

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0278-4

7 January 2021

Methemoglobinemia: a review and recommendations for management

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0278-4

7 January 2021

An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0278-4

7 January 2021

Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0278-4

7 January 2021

Esterase-activatable β-lapachone prodrug micelles for NQO1-targeted lung cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0278-4

7 January 2021

NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by β-lapachone.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0278-4

7 January 2021

Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ß-lapachone

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0278-4

7 January 2021

Depleting Tumor-NQO1 Potentiates Anoikis and Inhibits Growth of NSCLC.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0278-4

7 January 2021

The NQO1 bioactivatable drug, β-lapachone, alters the redox state of NQO1+ pancreatic cancer cells, causing perturbation in central carbon metabolism

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0278-4

7 January 2021

DT-diaphorase activity in NSCLC and SCLC cell lines: a role for fos/jun regulation

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0278-4

7 January 2021

Differential expression of the antioxidant response element within the hNQO1 promoter in NSCLC versus SCLC

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0278-4

7 January 2021

NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0278-4

7 January 2021

Isolation of x-ray-inducible transcripts from radioresistant human melanoma cells

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0278-4

7 January 2021

Induction of human NAD(P)H:quinone oxidoreductase (NQO1) gene expression by the flavonol quercetin

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0278-4

7 January 2021

Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0278-4

7 January 2021

Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors.

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0278-4

7 January 2021

Clinical implications of high NQO1 expression in breast cancers

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0278-4

7 January 2021

NQO1 protein expression predicts poor prognosis of non-small cell lung cancers

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0278-4

7 January 2021

High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0278-4

7 January 2021

Prognostic implication of NQO1 overexpression in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0278-4

7 January 2021

β-lapachone significantly increases the effect of ionizing radiation to cause mitochondrial apoptosis via JNK activation in cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0278-4

7 January 2021

β-Lapachone and Paclitaxel Combination Micelles with Improved Drug Encapsulation and Therapeutic Synergy as Novel Nanotherapeutics for NQO1-Targeted Cancer Therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41416-018-0278-4

7 January 2021

10.1038/S41416-018-0278-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30318513%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30318513%20AND%20SRC:MED&resulttype=core&format=json

28 April 2020

PubMed publication ID

30318513

1 reference